Androgen deprivation therapy should be used with caution in some prostate cancer cases, study warnsBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5043 (Published 22 September 2015) Cite this as: BMJ 2015;351:h5043
- Jacqui Wise
Combining androgen deprivation and radiotherapy is known to improve outcomes in aggressive prostate cancer, but research published in JAMA shows that it should be used with caution in men with coexisting illness.1
Six months of androgen deprivation therapy and radiation therapy is the standard treatment for unfavourable risk prostate cancer. But a post-randomisation analysis found that men with moderate or severe comorbidity showed no survival benefit from combined therapy. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial